Titre (en)
Analysis
2020
Racine
Analysis
2020
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (2020)

Index « Titre (en) » - entrée « covid »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
cov < covid < crescentic  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 167.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000011 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000013 (2020) Daniela Marotto [Italie] ; Piercarlo Sarzi-Puttini [Italie]What is the role of rheumatologists in the era of COVID-19?
000016 (2020) M. SilbersteinVitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
000020 (2020) Jared Radbel [États-Unis] ; Navaneeth Narayanan [États-Unis] ; Pinki J. Bhatt [États-Unis]Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.
000022 (2020) Luca Quartuccio [Italie] ; Luca Semerano [France] ; Maurizio Benucci [Italie] ; Marie-Christophe Boissier [France] ; Salvatore De Vita [Italie]Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome
000025 (2020) Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community
000032 (2020) Marc Feldmann [Royaume-Uni] ; Ravinder N. Maini [Royaume-Uni] ; James N. Woody [États-Unis] ; Stephen T. Holgate [Royaume-Uni] ; Gregory Winter [Royaume-Uni] ; Matthew Rowland [Royaume-Uni] ; Duncan Richards [Royaume-Uni] ; Tracy Hussell [Royaume-Uni]Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
000041 (2020) Hadir Shakshouk [États-Unis, Égypte] ; Maryam Daneshpazhooh [Iran] ; Dedee F. Murrell [Australie] ; Julia S. Lehman [États-Unis]Treatment considerations for patients with pemphigus during the COVID-19 pandemic
000042 (2020) Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis]Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
000045 (2020) Yong Xiong [République populaire de Chine] ; Yuan Liu [République populaire de Chine] ; Liu Cao [République populaire de Chine] ; Dehe Wang [République populaire de Chine] ; Ming Guo [République populaire de Chine] ; Ao Jiang [République populaire de Chine] ; Dong Guo [République populaire de Chine] ; Wenjia Hu [République populaire de Chine] ; Jiayi Yang [République populaire de Chine] ; Zhidong Tang [République populaire de Chine] ; Honglong Wu [République populaire de Chine] ; Yongquan Lin [République populaire de Chine] ; Meiyuan Zhang [République populaire de Chine] ; Qi Zhang [République populaire de Chine] ; Mang Shi [République populaire de Chine] ; Yingle Liu [République populaire de Chine] ; Yu Zhou [République populaire de Chine] ; Ke Lan [République populaire de Chine] ; Yu Chen [République populaire de Chine]Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
000049 (2020) Yeimer Ortiz-Martínez [Colombie]Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19.
000053 (2020) Jean-Marie Michot [France] ; Laurence Albiges [France] ; Nathalie Chaput [France] ; Veronique Saada [France] ; Fanny Pommeret [France] ; Franck Griscelli [France] ; Corinne Balleyguier [France] ; Benjamin Besse [France] ; Aurélien Marabelle [France] ; Florence Netzer [France] ; Mansouria Merad [France] ; Caroline Robert [France] ; Fabrice Barlesi [France] ; Bertrand Gachot [France] ; Annabelle Stoclin [France]Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
000055 (2020) Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine]Tocilizumab treatment in COVID-19: A single center experience.
000075 (2020) Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]Thoughts on COVID-19 and autoimmune diseases
000077 (2020) Lei Li [République populaire de Chine] ; Ranran Li [République populaire de Chine] ; Zhixiong Wu [République populaire de Chine] ; Xianghong Yang ; Mingyan Zhao [République populaire de Chine] ; Jiao Liu [République populaire de Chine] ; Dechang Chen [République populaire de Chine]Therapeutic strategies for critically ill patients with COVID-19
000083 (2020) Wen Zhang [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Fengchun Zhang [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Taisheng Li [République populaire de Chine] ; Zhengyin Liu [République populaire de Chine] ; Jinglan Wang [République populaire de Chine] ; Yan Qin [République populaire de Chine] ; Xuan Zhang [République populaire de Chine] ; Xiaowei Yan [République populaire de Chine] ; Xiaofeng Zeng [République populaire de Chine] ; Shuyang Zhang [République populaire de Chine]The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China
000084 (2020) Matthew Zirui Tay [Singapour] ; Chek Meng Poh [Singapour] ; Laurent Rénia [Singapour] ; Paul A. Macary [Singapour] ; Lisa F. P. Ng [Singapour, Royaume-Uni]The trinity of COVID-19: immunity, inflammation and intervention
000095 (2020) Chi Zhang [République populaire de Chine] ; Zhao Wu [République populaire de Chine] ; Jia-Wen Li [République populaire de Chine] ; Hong Zhao [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
000096 (2020) Tung-Hung Su [Taïwan] ; Jia-Horng Kao [Taïwan]The clinical manifestations and management of COVID-19-related liver injury
000097 (2020) Weiyi Tan ; Jamil AboulhosnThe cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease
000099 (2020) Carlo Perricone [Italie] ; Paola Triggianese [Italie] ; Elena Bartoloni [Italie] ; Giacomo Cafaro [Italie] ; Angelo F. Bonifacio [Italie] ; Roberto Bursi [Italie] ; Roberto Perricone [Italie] ; Roberto Gerli [Italie]The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i -k "covid" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i  \
                -Sk "covid" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    Title.i
   |clé=    covid
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021